Undenatured Type II Collagen for Leaky Gut Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Leaky gut syndrome, characterized by gaps in the intestinal wall allowing undigested food particles, bacteria, and toxins to enter the bloodstream, leading to inflammation and chronic diseases, is not effectively addressed by existing treatments.

Innovation Solution

Administering a native or undenatured type II collagen composition to mammals in amounts ranging from 1 mg to 1000 mg to reduce the effects of leaky gut syndrome and inflamed intestines, promoting intestinal health and balancing the intestinal microbiome.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for leaky gut syndrome, then general gastrointestinal support is provided, but the specific inflammation and microbiome imbalance are not effectively addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidtargeted therapeutic capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses specific probiotic strains (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis BB-12) as intermediary organisms that mediate between the compromised intestinal barrier and the underlying inflammation/microbiome imbalance, providing targeted therapeutic action that conventional treatments lack

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the therapeutic parameters by specifying exact probiotic strain combinations and dosages (e.g., 10^9 CFU per strain daily), transforming general gastrointestinal support into a precise, targeted treatment protocol that addresses specific pathological parameters like inflammation markers and microbiome composition

Inventive Principle:

Principle #35Parameter changes

2Productivity

If the intestinal barrier is compromised allowing particles to pass through, then absorption of nutrients occurs, but harmful substances enter the bloodstream causing inflammation

Engineering Contradiction:

Improvenutrient absorptionVSAvoidintestinal permeability to harmful substances

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by targeting specific regions and functions of the intestinal barrier - using probiotics that selectively enhance tight junction integrity in inflamed areas while maintaining overall permeability for nutrient absorption, thus differentiating between beneficial and harmful passage

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention converts the compromised barrier state into a therapeutic opportunity by introducing probiotics that exploit the altered intestinal environment to colonize and restore barrier function, turning the leaky gut condition into a pathway for beneficial microbial establishment and inflammation resolution

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260027188A1Method and Composition for Treating Conditions Associated with a Leaky Gut Barrier

Publication Date: 2026.01.29 LONZA GREENWOOD LLC

AI summary

The present disclosure is directed to a method for treating a mammal with leaky gut syndrome or having pre-stages of leaky gut syndrome. The method includes administering a composition that includes a native or undenatured type II collagen and/or a probiotic.